Risk factors for etiology and prognosis of mantle cell lymphoma

Expert Review of Hematology

Volumn 7, Issue 2, 2014, Pages 233-243

  Wang, Yu ^a   Ma, Shuangge ^b  

^a RENMIN UNIVERSITY OF CHINA   (China)

^b YALE UNIVERSITY   (United States)

Author keywords

Etiology; mantle cell lymphoma; prognosis; risk factors

Indexed keywords

BIOLOGICAL MARKER;

CANCER PROGNOSIS; CYTOGENETICS; FAMILY HISTORY; GENETIC ASSOCIATION; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; INFECTION; LIFESTYLE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA SEQUENCE;

BIOLOGICAL MARKERS; CYCLIN D1; HUMANS; LYMPHOMA, MANTLE-CELL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; SOXC TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896376113     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.889561     Document Type: Review

References (95)

1. The International Agency for Research on Cancer. In: Swerdlow S, Campo E, Harris NL, et al. editors. WHO Classification of tumours of haematopoietic and lymphoid tissue. 4th Edition. WHO; Geneva, Switzerland: 2008
2. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011;21:293-8
3. Howard O. Mantle cell lymphoma. In: Grossbard ML, editor. Malignant lymphomas (Atlas of Clinical Oncology) (Chapter 9). PMPH; USA: 2002
4. Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, et al. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma 2013;54(8):1677-83
5. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113(4):791-8
6. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer statistics review 1975- 2009. Based on November 2010 SEER data submission. National Cancer Institute; Bethesda, MD, USA
7. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17(12): 2257-317 (Pubitemid 38072572)
8. Zhang Y, Dai Y, Zheng T, Ma S. Risk factors of Non-Hodgkin lymphoma. Expert Opin Med Diagn 2011;5:539-50
9. International Lymphoma Epidemiology Consortium. Available from: epi.grants. cancer.gov/InterLymph
10. Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer 2008;122: 2062-70 (Pubitemid 351441197)
11. Morton LM, Zheng T, Holford TR, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 2005;6:469-76 (Pubitemid 40903627)
12. Morton LM, Hartge P, Holford TR, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the international lymphoma epidemiology consortium (interlymph). Cancer Epidemiol Biomarkers Prev 2005;14:925-33 (Pubitemid 40478558)
13. Kricker A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non-Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer 2008;122:144-54 (Pubitemid 350209989)
14. Vajdic CM, Falster MO, de Sanjose S, et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res 2009;69:6482-9
15. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008;23:1-37
16. Eriksson M, Hardell L, Carlberg M, Akerman M. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer 2008;123:1657-63
17. Cocco P, t'Mannetje A, Fadda D, et al. Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study. Occup Environ Med 2010;67:341-7
18. Kane EV, Newton R. Occupational exposure to gasoline and the risk of non-Hodgkin lymphoma: a review and meta-analysis of the literature. Cancer Epidemiol 2010;34:516-22
19. Ma S. Risk factors of follicular lymphoma. Expert Opin Med Diagn 2012;6(4):323-33
20. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-8 (Pubitemid 351447318)
21. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011;118(11):3088-95
22. Munksgaard L, Obitz ER, Goodlad JR, et al. Demonstration of B. burgdorferi-DNA in two cases of nodal lymphoma. Leuk Lymphoma 2004;45: 1721-3 (Pubitemid 38886027)
23. Scholkopf C, Melbye M, Munksgaard L, et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood 2008;111: 5524-9
24. Aberer E, Fingerle V, Wutte N, et al. Within European margins. Lancet 2011;377:178
25. Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97:586-91 (Pubitemid 36125835)
26. Rule SA, Poplar S, Evans PA, et al. Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. J Clin Oncol 2011;29:e437-9
27. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;109: 3479-88 (Pubitemid 46572538)
28. Tort F, Camacho E, Bosch F, et al. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004;89(3): 314-19 (Pubitemid 38788416)
29. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7: 750-62.An early review of molecular risk factors. (Pubitemid 47463673)
30. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-21 (Pubitemid 41775942)
31. Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 2013;121(8): 1394-402
32. Herens C, Lambert F, Quintanilla-Martinez L, et al. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood 2008;111(3): 1745-6 (Pubitemid 351213474)
33. Seto M. Cyclin D1-negative mantle cell lymphoma. Blood 2013;121(8):1249-50
34. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216-22 (Pubitemid 46640567)
35. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119(9):1963-71
36. Meissner B, Kridel R, Lim RS, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013;121(16):3161-4
37. Hutter G, Scheubner M, Zimmermann Y, et al. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14 (ARF)] in mantle cell lymphoma. Genes Chromosomes Cancer 2006;45(2):203-10 (Pubitemid 43191027)
38. Setoodeh R, Schwartz S, Papenhausen P, et al. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol 2013;6(2):155-67
39. Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology 2012;61(4):685-93
40. Schilling G, Penas EM, Janjetovic S, et al. Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus. Leuk Res 2013;37:280-6
41. Salaverria I, Espinet B, Carrio A, et al. Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer 2008;47(12):1086-97
42. Kawamata N, Ogawa S, Gueller S, et al. Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 2009;37:937-46
43. Bea S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009;113(13):3059-69
44. Menanteau MR, Martinez-Climent JA. Genomic profiling of mantle cell lymphoma. In: Banerjee D, Shah SP, editors. Array comparative genomic hybridization: protocols and applications, methods in molecular biology. Volume 973. Springer; 2013. p. 147-63.Comprehensive discussions on genome-wide profiling in mantle cell lymphoma (MCL).
45. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010;116(6):953-61
46. Rubio-Moscardo F, Blesa D, Mestre C, et al. Characterization of 8p21.3 chromosomal deletions in b-cell lymphoma: trail-r1 and trail-r2 as candidate dosage-dependent tumor suppressor genes. Blood 2005;106(9):3214-22 (Pubitemid 41565921)
47. Pinyol M, Bea S, Pla L, et al. Inactivation of rb1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007;109(12):5422-9 (Pubitemid 46890565)
48. Kato M, Sanada M, Kato I, et al. Frequent inactivation of a20 in b-cell lymphomas. Nature 2009;459(7247):712-16
49. Ek Sm Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111(2):800-5
50. Meggendorfer M, Kern W, Haferlach C, et al. SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis. Leukemia 2013;27(12):2388-91
51. Vegliante MC, Palomero J, Perez-Galan P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013;121(12):2175-85
52. Hamborg KH, Bentzen HH, Grubach L, et al. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma. Eur J Haematol 2012;89:385-94
53. Wasik AM, Lord M, Wang X, et al. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression. Sci Rep 2013;3:1400
54. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001; 61(2):2409-12 (Pubitemid 32685815)
55. Gelebart P, Zak Z, Anand M, et al. Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS One 2012;7(4):e33738
56. Fernberg P, Chang ET, Duvefelt K, et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010;21:759-69
57. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010;171:267-76
58. Smedby KE, Foo JN, Skibola CF, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011;7: e1001378
59. Galimberti S, Nagy B, Palumbo GA, et al. Vascular endothelial growth factor polymorphisms in mantle cell lymphoma. Acta Haematol 2010;123:91-5
60. Shaknovich R, Melnick A. Epigenetics and B-cell lymphoma. Curr Opin Hematol 2011;18(4):293-9
61. Leshchenko VV, Kuo PY, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010;116(7):1025-34
62. Husby S, Geisler C, Gronbaek K. MicroRNAs in mantle cell lymphoma. Leuk Lymphoma 2013;54(9):1867-75
63. Jima DD, Zhang J, Jacobs C, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010;116(23):e118-27
64. Jardin F, Figeac M. MicroRNAs in lymphoma, from diagnosis to targeted therapy. Curr Opin Oncol 2013;25(5): 480-6
65. Cecconi D, Zamo A, Bianchi E, et al. Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 2008;8:4495-506
66. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558-65
67. Hoster E. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin Hematol 2011;48(3):185-8
68. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107(8): 3407
69. Majlis A, Pugh WC, Rodriguez MA, et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997;15:1664-71 (Pubitemid 27167407)
70. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131(1):29-38 (Pubitemid 43899705)
71. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21(23):4407-12 (Pubitemid 46621818)
72. Wang X, Asplund AC, Porwit A, et al. The subcell pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008;143(2):248-52
73. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96(8):1121-7
74. Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119(18):4215-23
75. Navarro A, Clot G, Royo C, et al. Status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72(20):5307-16
76. Molavi O, Wang P, Zak Z, et al. Gene methylation and silencing of SOCS3 in mantle cell Lymphoma. Br J Haematol 2013;161:348-56
77. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97 (Pubitemid 37443390)
78. Boukhiar MA, Roger C, Tran J, et al. Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. Exp Hematol Oncol 2013;2(1): 4
79. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999;93(12):4365-74 (Pubitemid 29279280)
80. Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010;49(5): 439-51
81. Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with cgh to bac microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105(11):4445-54 (Pubitemid 40720793)
82. Vaishampayan UN, Mohamed AN, Dugan MC, et al. Blastic mantle cell lymphoma associated with Burkitt-type translocation and hypodiploidy. Br J Haematol 2001;115(1):66-8 (Pubitemid 32995095)
83. Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006;103(7):2352-7 (Pubitemid 43271673)
84. Royo C, Salaverria I, Hartmann EM, et al. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011;21(5):322-34
85. Enjuanes A, Fernandez V, Hernandez L, et al. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. PLoS One 2011;6(5):e19736
86. Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012;119(21):4939-48
87. Goswami RS, Atenafu EG, Xuan Y, et al. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol 2013;31(23):2903-11
88. Navarro A, Clot G, Prieto M, et al. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res 2013;19(12):3121-9
89. Pott C. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. Semin Hematol 2011;48(3):172-84
90. Rebbeck TR, Ambrosone CB, Shields PG. editors. Molecular epidemiology. Applications in cancer and other human diseases. Informa Healthcare; NY, USA: 2008
91. Wang ML, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in relapsed or refractory mantel-cell lymphoma. N Engl J Med 2013;369(6):507-16
92. Sanchez-Tillo E, Fanlo L, Siles L, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ 2014;21(2):247-57
93. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of Alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non- Hodgkin lymphomas. J Clin Oncol 2014; 32(1):44-50
94. Colomer D, Campo E. Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. Cancer Cell 2014;25(1):7-9
95. Camara-Clayette V, Koscienlny S, Roux S, et al. BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma. PLoS One 2013;8(9):e73993